BMS Buying Padlock For Up To $600 Million
This article was originally published in Start Up
Executive Summary
Two years, $18 million and a big pharma buyout for up to $600 million? That's a great return for investors in Padlock Therapeutics, a biotech firm that raised a single venture capital round in late 2014 to develop novel treatments for autoimmune diseases before Bristol-Myers Squibb agreed to buy the company.
You may also be interested in...
Finance Watch: J&J Notes JLabs Incubators' Success Stories To Date
Private Company Edition: Life science firms in J&J's JLabs incubators have raised $9.4bn to date from deals and financings, including five IPOs. Also, October brings a wide range of new equity and VC financings.
Venture Funding Deals: LAM Nabs $58m Series C One Year After $40m Round
Also, Advicenne doubles its fundraising to date; Michael Gilman-helmed Arrakis raises a $38m Series A; Breath spins out with $46m; and Spero gets $51.7m for novel antibacterials.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.